Cargando…
The anti-Trop-2 antibody-drug conjugate Sacituzumab Govitecan—effectiveness, pitfalls and promises
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9347060/ https://www.ncbi.nlm.nih.gov/pubmed/35928735 http://dx.doi.org/10.21037/atm-22-621 |
| _version_ | 1784761782301097984 |
|---|---|
| author | Guerra, Emanuela Alberti, Saverio |
| author_facet | Guerra, Emanuela Alberti, Saverio |
| author_sort | Guerra, Emanuela |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9347060 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | AME Publishing Company |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-93470602022-08-03 The anti-Trop-2 antibody-drug conjugate Sacituzumab Govitecan—effectiveness, pitfalls and promises Guerra, Emanuela Alberti, Saverio Ann Transl Med Editorial Commentary AME Publishing Company 2022-05 /pmc/articles/PMC9347060/ /pubmed/35928735 http://dx.doi.org/10.21037/atm-22-621 Text en 2022 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/. |
| spellingShingle | Editorial Commentary Guerra, Emanuela Alberti, Saverio The anti-Trop-2 antibody-drug conjugate Sacituzumab Govitecan—effectiveness, pitfalls and promises |
| title | The anti-Trop-2 antibody-drug conjugate Sacituzumab Govitecan—effectiveness, pitfalls and promises |
| title_full | The anti-Trop-2 antibody-drug conjugate Sacituzumab Govitecan—effectiveness, pitfalls and promises |
| title_fullStr | The anti-Trop-2 antibody-drug conjugate Sacituzumab Govitecan—effectiveness, pitfalls and promises |
| title_full_unstemmed | The anti-Trop-2 antibody-drug conjugate Sacituzumab Govitecan—effectiveness, pitfalls and promises |
| title_short | The anti-Trop-2 antibody-drug conjugate Sacituzumab Govitecan—effectiveness, pitfalls and promises |
| title_sort | anti-trop-2 antibody-drug conjugate sacituzumab govitecan—effectiveness, pitfalls and promises |
| topic | Editorial Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9347060/ https://www.ncbi.nlm.nih.gov/pubmed/35928735 http://dx.doi.org/10.21037/atm-22-621 |
| work_keys_str_mv | AT guerraemanuela theantitrop2antibodydrugconjugatesacituzumabgovitecaneffectivenesspitfallsandpromises AT albertisaverio theantitrop2antibodydrugconjugatesacituzumabgovitecaneffectivenesspitfallsandpromises AT guerraemanuela antitrop2antibodydrugconjugatesacituzumabgovitecaneffectivenesspitfallsandpromises AT albertisaverio antitrop2antibodydrugconjugatesacituzumabgovitecaneffectivenesspitfallsandpromises |